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Abstract
Prostaglandins have been implicated in several neovascular diseases. In the present study, we
found elevated FP receptor and vascular endothelial growth factor (VEGF) expression colocalized
in glandular epithelial and vascular cells lining the blood vessels in endometrial adenocarcinomas.
We investigated the signaling pathways activated by the FP receptor and their role in modulating
VEGF expression in endometrial adenocarcinoma (Ishikawa) cells. Ishikawa cells were stably
transfected with FP receptor cDNA in the sense or antisense orientations. Treatment of Ishikawa
cells with prostaglandin F2α (PGF2α) rapidly induced transphosphorylation of the epidermal
growth factor receptor (EGFR) and phosphorylation of extracellular signal-regulated kinase
(ERK) 1/2 via the FP receptor. Activation of EGFR-Ras-mitogen-activated protein kinase/ERK
kinase (MEK) signaling via the FP receptor resulted in an increase in VEGF promoter activity,
expression of VEGF mRNA, and secretion of VEGF protein. These effects of PGF2α on the FP
receptor could be abolished by treatment of cells with a specific FP receptor antagonist, chemical
inhibitors of c-Src, matrix metalloproteinase, and EGFR kinase or by inactivation of signaling
with dominant-negative mutant isoforms of EGFR, Ras, or MEK or with small inhibitory RNA
oligonucleotides targeted against the EGFR. Finally, we confirmed that PGF2α could potentiate
angiogenesis in endometrial adenocarcinoma explants by transactivation of the EGFR and
induction of VEGF mRNA expression.
Introduction
Over the past decade, a role has been established for cyclooxygenase (COX) enzymes and
prostaglandins in the development and progression of inflammation and cancer (1, 2). Of
particular significance to female reproductive health are the observations that reproductive
tract cancers, such as endometrial adenocarcinoma and cervical carcinoma, which highly
express COX enzymes, also contain elevated levels of prostaglandins and expression and
signaling of prostanoid G protein–coupled receptors (GPCR; refs. 3-6). These findings
suggest that aberrant prostanoid receptor signaling may be key toward the regulation or
progression of female reproductive tract pathologies, such as endometrial adenocarcinoma.
In the reproductive tract, the E and F series of prostaglandins are the most abundantly
biosynthesized prostanoids, and prostaglandin F2α (PGF2α) is a major metabolite of COX
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enzymes in human endometrium (7, 8). Currently, there are three known isoforms of COX
enzyme, COX-1, COX-2, and COX-3 (a splice variant of COX-1; refs. 3, 9). PGF2α is
biosynthesized from arachidonic acid by a series of oxidation steps by COX enzymes and
PGF synthase, respectively (10). Following biosynthesis, PGF2α is transported out of the
cell by a prostaglandin transporter (11) where it exerts an autocrine/paracrine function
through GPCR-mediated interaction. The GPCR for the human PGF2α (FP receptor) has
been cloned, and its activation leads to coupling to the G protein Gq and release of
inositol-1,4,5-trisphosphate and diacylglycerol (12).
Recently, we have reported elevated expression of the FP receptor in human endometrial
adenocarcinomas and ascertained a role for PGF2α in enhancing the proliferation of
endometrial adenocarcinoma cells (6), confirming an autocrine/paracrine regulation of
neoplastic cell function by PGF2α-FP receptor interaction. Prostanoid biosynthesis and
signaling, including PGF2α, have been implicated in numerous endometrial pathologies,
including excessive menstrual bleeding (menorrhagia), endometriosis, and dysmenorrhea (7,
13, 14).
Like many other solid tumors, the growth and proliferation of endometrial adenocarcinoma
is dependent on angiogenesis, the formation of new blood vessels from the preexisting
vascular bed (15). Of the numerous proangiogenic factors reported to date, vascular
endothelial growth factor (VEGF) is the progenitor in the mediation of tumor angiogenesis
(16). Elevated expression of VEGF in human tumor biopsies has been reported in various
carcinomas, including endometrial adenocarcinoma (17). Recently, a role for the E-series
prostanoid receptors in angiogenesis has been established ( for review, see ref. 3). However,
little is known about FP receptor signaling to angiogenic factors, such as VEGF.
In this study, we investigated the potential role of elevated FP receptor expression and
signaling in modulating vascular function in endometrial adenocarcinomas. We found
elevated FP receptor and VEGF expression in endometrial adenocarcinomas, colocalized in
glandular epithelial and endothelial cells. We investigated the signal transduction pathways
associated with VEGF expression via the FP receptor using an endometrial adenocarcinoma
(Ishikawa) cell model system. We found that PGF2α rapidly augments the activation of the
extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway in a c-Src-, matrix
metalloproteinase (MMP)-, epidermal growth factor receptor (EGFR)-, and Ras-dependent
manner via the FP receptor. Activation of the EGFR-Ras-mitogen-activated protein kinase
(MAPK)/ERK kinase (MEK)-ERK1/2 pathway resulted in an increase in VEGF promoter
activity, VEGF mRNA expression, and secretion of VEGF protein. Finally, using human
endometrial adenocarcinoma explants, we confirmed that PGF2α could potentiate
tumorigenesis in situ by transactivating the EGFR and inducing the expression of VEGF to
promote angiogenesis.
Materials and Methods
Reagents
Culture medium was purchased from Life Technologies (Paisley, United Kingdom).
Penicillin-streptomycin and FCS were purchased from PAA Laboratories (Middlesex,
United Kingdom). The c-Myc (sc-40), EGFR (sc-03), phospho-EGFR (sc-12351), and ERK
(sc-93) antibodies were purchased from Santa Cruz Biotechnology/Autogen-Bioclear
(Wiltshire, United Kingdom). The FP receptor antibody (101802) was purchased from
Cayman Chemical Co./Alexis Corp. (Nottingham, United Kingdom). Anti-phospho-p42/p44
ERK (9101), phospho-p38 (9211), total p38 (9212), phospho–c-Jun NH2-terminal kinase
(JNK; 9251), and total JNK (9252) antibodies were purchased from Cell Signaling
Technologies/New England Biolabs (Herts, United Kingdom). The CD31 antibody was
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purchased from DAKO Corp. (High Wycombe, United Kingdom). Alkaline phosphatase
secondary antibodies, indomethacin, PBS, bovine serum albumin, and PGF2α were
purchased from Sigma Chemical Co. (Dorset, United Kingdom). ECF chemiluminescence
system was purchased from Amersham Biosciences (Buckinghamshire, United Kingdom).
PD98059 (18.7 mmol/L stock in DMSO), PP2 (10 mmol/L stock in DMSO), GM6001 (10
mmol/L stock in DMSO), GF109203X (10 mmol/L stock in DMSO), and AG1478 (10
mmol/L stock in DMSO) were purchased from Calbiochem (Nottingham, United Kingdom)
and stored at -20°C.
Patients and Tissue Collection
Endometrial adenocarcinoma tissue (n = 25) was collected from women undergoing
hysterectomy who had been prediagnosed to have adenocarcinoma of the uterus. All women
were postmenopausal and had received no treatment before surgery. The ages of the patients
ranged from 50 to 71 years with a median age of 60.5 years. Hysterectomy specimens for
adenocarcinoma were collected from the operating theatre and placed on ice. With minimal
delay, the specimens were opened by a gynecologic pathologist. Small samples (~5 mm-3
cm) of polypoidal adenocarcinoma tissue were collected from the endometrial lumen,
transferred into neutral-buffered formalin (and wax embedded for immunofluorescence
studies), snap frozen in dry ice, and stored at -70°C ( for RNA extraction), and placed in
RPMI 1640 containing 2 mmol/L L-glutamine, 100 units penicillin, 100 μg/mL
streptomycin, and 3 μg/mL indomethacin (to inhibit endogenous COX activity) for in vitro
culture. The diagnosis of adenocarcinoma was confirmed histologically in all cases and the
percentage of tumor cells to stroma was estimated to be ~75%:25%. Normal endometrial
tissue (n = 10) at different stages of the menstrual cycle was collected from women
undergoing surgery for minor gynecologic procedures with no underlying endometrial
pathology with an endometrial suction curette (Pipelle, Laboratoire CCD, Paris, France)
from women with regular menstrual cycles (25-35 days) and processed exactly as described
above. The ages of the control women ranged from 21 to 39 years with a median age of 30.5
years. None of the control women had received a hormonal preparation in the 3 months
preceding biopsy collection. Biopsies were dated according to the stated last menstrual
period and confirmed by histologic assessment according to the criteria of Noyes et al. (18).
Ethical approval was obtained from Lothian Research Ethics Committee and written
informed consent was obtained from all subjects before tissue collection.
Cell Culture
Ishikawa endometrial adenocarcinoma cells (European Collection of Cell Culture, Wiltshire,
United Kingdom) were maintained as described previously (6). Stable FP transfectant cells
were maintained under the same conditions with the addition of a maintenance dose of 200
μg/mL G418.
FP Receptor Amplification and Cell Transfections
The FP receptor cDNA clone and stable cell lines were constructed by Cytomix Ltd.
(Cambridge, United Kingdom). The FP receptor cDNA was amplified from a human lung
cDNA library from the Genbank accession no. NM_000959 by PCR using the proofreading
polymerase Pfu (Stratagene, Amsterdam, The Netherlands). The product was directionally
cloned into the mammalian expression vector gWIZ3.0 (Gene Therapy Systems, Cambridge,
United Kingdom), in both sense and antisense directions, and the orientation of the construct
was confirmed by automated DNA sequencing. The FP receptor cDNA was transfected into
Ishikawa cells at passage 10 in the sense and antisense directions. Control cells transfected
with pcDNA6/V5/His/LacZ (Invitrogen, De Schelp, The Netherlands) cDNA and assayed
with β-galactosidase were used to determine a transfection efficiency of 45 ± 5%. Individual
cell populations were selected for with addition of 800 μg/mL G418. Full selection was
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confirmed by the 100% death of nontransfected control cells, and 11 single FP receptor
sense and antisense clones were selected and expanded for Western blot analysis. The clones
with the highest level of FP receptor expression [FP sense (FPS)] and lowest receptor
expression [FP antisense (FPAS)] were expanded and stored in liquid nitrogen. Based on the
relative quantification of FP receptor expression, two sense clones (S32 and S22) and two
antisense clones (A14 and A19) exhibiting similar phenotypic and biochemical alterations
were supplied. The results of our studies using the S32 and A19 clones are presented here.
Immunofluorescent Microscopy
Cells—Approximately 10,000 wild-type (WT), FPS, and FPAS cells were seeded in
chamber slides, fixed in methanol, washed in PBS, and blocked using 5% normal swine
serum. Subsequently, the cells were incubated with polyclonal rabbit anti–FP receptor
antibody at a dilution of 1:50 at 4°C for 18 hours followed by swine anti-rabbit
tetramethylrhodamine isothiocyanate (DAKO) at 25°C for 20 minutes and counterstained
with To-Pro-3 (Molecular Probes, Inc., Eugene, OR) at a dilution of 1:2,000 for 2 minutes.
Cells were then mounted in Permafluor (Immunotech-Coulter, Buckinghamshire, United
Kingdom) and coverslipped. Control cells were incubated with rabbit IgG.
Tissues—FP receptor and VEGF or CD31 protein expression were colocalized in
endometrial adenocarcinomas (n = 12) by dual immunofluorescence immunohistochemistry.
Tissue sections were prepared as described previously (6) and blocked using 5% normal
horse ( for FP/VEGF) or normal goat ( for FP/CD31) serum diluted in PBS. Subsequently,
sections were incubated with either goat anti-VEGF antibody at a dilution of 1:50 or mouse
anti-CD31 antibody (1:30) for 18 hours at 4°C. Control sections were incubated with goat or
mouse IgG, respectively. Thereafter, sections were washed with PBS and incubated with
biotinylated horse antigoat for FP/VEGF or goat anti-mouse IgG (DAKO) followed by
incubation with the fluorochrome streptavidin Alexa Fluor 488 (Molecular Probes) diluted
1:200 in PBS. Sections were reblocked with 5% normal goat serum diluted in PBS and
incubated with rabbit anti–FP receptor antibody at a dilution of 1:100 at 4°C for 18 hours.
Control sections were incubated with rabbit IgG. Thereafter, the cells were washed in PBS
and incubated with the fluorochrome streptavidin Alexa Fluor 546 diluted 1:200 in PBS at
25°C for 20 minutes. Cells were mounted in Permafluor and coverslipped. Fluorescent
images were visualized and photographed using a Carl Zeiss (Jena, Germany) laser scanning
microscope LM510.
Protein Extraction
Cells—For EGFR transactivation studies, 3 × 106 cells were seeded in 10 cm dishes, and
for MAPK studies, 1 × 106 cells were seeded in 5 cm dishes. The following day cells were
incubated in serum-free culture medium and 8.4 μmol/L indomethacin (a dual COX enzyme
inhibitor used to inhibit endogenous prostanoid biosynthesis) for at least 16 hours. The next
day, cells were pretreated with specific inhibitors for c-Src (PP2, 10 μmol/L), MMP
(GM6001, 10 μmol/L), EGFR kinase (AG1478, 100 nmol/L), or MEK (PD98059, 50 μmol/
L) or FP receptor antagonist AL8810 (Calbiochem) or vehicle for 1 hour before stimulation
with 100 nmol/L PGF2α ( for the period specified in the figure legends) or vehicle.
Following stimulation with PGF2α, proteins were extracted and quantified as described
previously (6). The protein content in the supernatant fraction was determined using protein
assay kits (Bio-Rad, Hemel Hempstead, United Kingdom).
Tissue—For EGFR transactivation studies, carcinoma tissue (n = 4) explants were finely
chopped using a sterile scalpel blade and incubated in serum-free medium for at least 12
hours containing penicillin/streptomycin (as described previously) and 8.4 μmol/L
indomethacin. The next day, tissue was pretreated with 50 μmol/L AL8810 or 100 nmol/L
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AG1478 for 1 hour before stimulation with 100 nmol/L PGF2α for 10 minutes. Following
stimulation with PGF2α, tissue was washed with PBS and protein was harvested by
homogenization in protein lysis buffer, clarified by centrifugation, and assayed as described
above before immunoprecipitation and/or Western blot analysis.
Immunoprecipitation and Western Blot Analysis
For immunoprecipitation studies, equal amounts of protein were incubated with specific
EGFR or c-Myc antibody preconjugated to protein A-Sepharose overnight at 4°C with
gentle rotation. Beads were washed extensively with lysis buffer and immune complexes
were solubilized in Laemmli buffer [125 mmol/L Tris-HCl (pH 6.8), 4% SDS, 5% 2-
mercaptoethanol, 20% glycerol, 0.05% bromophenol blue] and then boiled for 5 minutes.
For FP receptor expression in cells and MAPK studies, a total of 50 μg of protein was
resuspended in 20 μL Laemmli buffer. Proteins were resolved and immunoblotted as
described previously (6) and incubated with specific primary and alkaline phosphatase–
conjugated secondary antibodies. Immunoreactive proteins were visualized by the ECF
chemiluminescence system according to the manufacturer’s instructions. Proteins were
revealed and quantified by PhosphorImager analysis using the Typhoon 9400 system
(Molecular Dynamics/Amersham Biosciences). Relative density in immunoblots was
calculated by dividing the value obtained from the phosphorylated blots by the value
obtained from total protein blots and expressed as fold above vehicle controls. All data are
presented as mean ± SE.
Total Inositol Phosphate Assays
Total inositol phosphate production was measured in Ishikawa WT, FPS, and FPAS cells
treated either with vehicle, 100 nmol/L PGF2α, or PGF2α and increasing doses of AL8810
and assayed as described previously (19). Data are presented as mean ± SE.
Taqman Quantitative Reverse Transcription-PCR
FP receptor and VEGF (n = 25 carcinoma and n = 10 normal tissues) expression in
endometrial tissues and VEGF expression in FPS cells was measured by quantitative reverse
transcription-PCR (RT-PCR) analysis as described previously (20). Cells were synchronized
by serum withdrawal for at least 12 hours in serum-free medium containing 8.4 μmol/L
indomethacin. Carcinoma explants were finely chopped using a sterile scalpel blade and
incubated in serum-free medium for at least 12 hours. Thereafter, medium was removed and
replaced with fresh medium containing indomethacin with either 100 nmol/L PGF2α,
vehicle, or 100 nmol/L PGF2α and chemical inhibitor for the time indicated in the figure
legends. RNA was extracted using Tri-reagent (Sigma Chemical) following the
manufacturer’s guidelines. Once extracted and quantified, RNA samples were reverse
transcribed and subjected to RT-PCR analysis using an ABI Prism 7700 as described
previously (6, 20). VEGF and FP primers and probe for quantitative PCR were designed
using the PRIMER express program (PE Applied Biosystems, Warrington, United
Kingdom) as described previously (6, 20). Data were analyzed and processed using
Sequence Detector version 1.6.3 (PE Applied Biosystems). Expression of VEGF/FP was
normalized to RNA loading for each sample using the 18S rRNA as an internal standard.
Results are expressed as fold increase above vehicle treated cells.
Transient Transfections
Cell signaling to ERK1/2 was determined using dominant-negative (DN) isoforms targeted
against Ras GTPase, EGFR, and MEK. The transfection efficiency of Ishikawa cells had
been determined as described earlier and the plasmids for the various ERK cascade members
were described recently (21-24). In addition, small interfering RNAs (siRNA) were used to
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abolish EGFR expression and function using a siRNA/siAB assay kit (Upstate, Milton
Keynes, United Kingdom). Transfection efficiency of siRNA experiments was determined
by immunofluorescence microscopy as 48 ± 5% using a fluorescein-labeled siRNA. Briefly,
Ishikawa sense cells were seeded to a density of 5 × 105 cells per well in 6 cm dishes and
exposed to either 300 nmol/L EGFR siRNA or 100 nmol/L control random siRNA or 5 μg
c-Myc-ERK1/2 and DN-Ras, DN-EGFR, DN-MEK, or empty vector plasmid (pcDNA3) in
the presence of Superfect (Qiagen, Crawley, United Kingdom) for 4 hours and then cultured
for 24 hours in complete medium. Thereafter, cells were serum starved for 24 hours in
medium containing indomethacin and then exposed to 100 nmol/L PGF2α or vehicle for 10
minutes. Thereafter, cells were lysed and protein was quantified and subjected to Western
blot analysis as described above.
VEGF ELISA
Secreted VEGF was measured by ELISA. Cells were first synchronized by serum
withdrawal for 12 hours in serum-free medium containing 8.4 μmol/L indomethacin.
Thereafter, medium was removed and replaced with fresh serum-free medium containing
indomethacin and vehicle, 100 nmol/L PGF2α, or 100 nmol/L PGF2α and AL8810 for 24
hours. Culture medium was removed and VEGF protein was measured using a Human
VEGF ELISA kit according to the manufacturer’s instruction (Oncogene, Nottingham,
United Kingdom). Data are expressed as fold increase where the amount of VEGF secreted
in treated cells is divided by the amount secreted in cells treated with the vehicle. The data
are presented as mean ± SE from three independent experiments.
VEGF Luciferase Reporter Assays
The VEGF reporter plasmid (kindly supplied by Prof. Keping Xie, Department of
Gastrointestinal Medical Oncology and Cancer Biology, The University of Texas M.D.
Anderson Cancer Center, Houston, TX; ref. 25) containing the firefly luciferase reporter was
cotransfected into Ishikawa cells in triplicate with an internal control pRL-TK (containing
the Renilla luciferase coding sequence; Promega, Southampton, United Kingdom) and either
control vector (pcDNA3.0) or vector encoding a DN-Ras, DN-EGFR, and DN-MEK. Cells
were transfected using Superfect for 6 hours. The following day, the cells were serum
starved for at least 18 hours with indomethacin before stimulation for 8 hours with vehicle,
PGF2α, or PGF2α and AL8810. The activity of both firefly and Renilla luciferase was
determined using the dual luciferase assay kit. Fold increase in luciferase activity was
calculated by dividing the relative luciferase activity in cells treated with PGF2α by the
relative luciferase activity in cells treated with vehicle.
Statistics
Where appropriate, data were subjected to statistical analysis with ANOVA and Fisher’s
protected least significant difference tests (Statview 5.0, Abacus Concepts, Inc., Carpenteria,
CA).
Results
FP receptor and vascular endothelial growth factor expression in endometrial
adenocarcinoma and normal endometrium
The expression of FP receptor and VEGF mRNA was significantly up-regulated in all cases
of endometrial adenocarcinoma investigated compared with normal endometrium (P < 0.05)
as determined by Taqman quantitative RT-PCR analysis (Fig. 1A). No correlation was
observed between levels of expression of FP receptor and VEGF mRNA and grade or stage
of carcinoma. The relative expression of FP receptor and VEGF in endometrial
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adenocarcinomas was determined to be 53.7 ± 16.9 and 32.5 ± 10.2, respectively, compared
with expression in normal endometrium (0.4 ± 0.12 and 1.12 ± 0.25 for FP receptor and
VEGF, respectively).
Colocalization of FP receptor with vascular endothelial growth factor or CD31 in
endometrial adenocarcinomas
FP receptor and VEGF expression was colocalized in endometrial adenocarcinomas by dual
immunofluorescence immunohistochemistry (Fig. 1B). FP receptor expression and VEGF
expression were localized together (FP/VEGF) in the glandular epithelial and endothelial
compartment in all poorly, moderately, and well-differentiated endometrial
adenocarcinomas. To confirm that FP receptor was localized to the endothelial cells of blood
vessels, we did dual immunofluorescence immunohistochemistry on tissue sections using
antibodies raised against the FP receptor and CD31 endothelial cell marker (Fig. 1C). FP
receptor (FP) colocalized (FP/CD31) in the blood vessels with CD31 in all endometrial
adenocarcinomas. Incubating sections with nonimmune IgG from the host species abolished
the immunoreactivity.
FP receptor expression in Ishikawa cells
FP receptor expression was assessed in stably transfected Ishikawa cells overexpressing the
FP receptor in the sense (FPS) and antisense (FPAS) orientations. Western blot analysis
(Fig. 2A) and immunofluorescence microscopy (Fig. 2B) showed elevated FP receptor
expression in FPS cells and reduced FP expression in FPAS cells compared with WT cells.
FP receptor expression was localized to the plasma membrane (Fig. 2B) and was abolished
by incubating cells with rabbit IgG in place of antibody (Fig. 2B, control representative of
FPS cells, and Fig. 2C). Quantitative RT-PCR analysis was then used to compare FP
receptor expression in WT and FPS Ishikawa cells with FP receptor expression detected in
normal endometrium and endometrial adenocarcinomas in vivo. As shown in Fig. 2C, the
relative FP receptor mRNA expression in FPS cells and adenocarcinoma tissues was
significantly greater than the FP receptor expression in WT Ishikawa cells or normal
endometrial tissue (P < 0.05). FP receptor couples to Gq resulting in increased formation of
inositol phosphate. We measured total inositol phosphate accumulation in WT, FPS, and
FPAS cells in response to administration of 100 nmol/L PGF2α. A significant increase in
inositol phosphate accumulation was observed in FPS cells compared with WT and FPAS
cells following treatment with PGF2α (P < 0.05; Fig. 2D). Treatment of FPS cells with the
selective FP receptor antagonist AL8810 (26) dose-dependently reduced the agonist-induced
inositol phosphate accumulation (P < 0.05; Fig. 2D).
Prostaglandin F2α-FP receptor activation of mitogen-activated protein kinase signaling
The effect of PGF2α on the activation of the downstream MAPK signaling pathways
(ERK1/2, p38, and JNK) was determined after treatment of WT, FPS, and FPAS Ishikawa
cells with 100 nmol/L PGF2α. Stimulation of Ishikawa cells with PGF2α caused a rapid and
augmented activation of ERK1/2 in FPS compared with WT and FPAS cells (Fig. 3A). The
peak of ERK1/2 activation was observed after 10 minutes in Ishikawa FPS treated with 100
nmol/L PGF2α (Fig. 3A, lane 5) compared with cells treated with vehicle alone (Fig. 3A,
lane 4). No significant phosphorylation of p38 or JNK MAPK was observed in WT, FPS, or
FPAS cells following treatment of cells with 100 nmol/L PGF2α within the period of
activation of ERK1/2 (data not shown). Cotreatment of Ishikawa WT, FPS, and FPAS cells
with the selective FP receptor antagonist AL8810 dose-dependently inhibited the activation
of ERK1/2, indicating that the ERK1/2 activation was mediated via direct PGF2α-FP
receptor interaction (Fig. 3B).
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Prostaglandin F2α-FP receptor activation of extracellular signal-regulated kinase 1/2
signaling requires epidermal growth factor receptor kinase activity
We next evaluated the effect of the selective inhibitors of MEK (PD98059), MMP
(GM6001), c-Src (PP2), and EGFR kinase (AG1478) on the PGF2α-induced activation of
ERK1/2 signaling in FPS cells. Treatment of FPS cells with 100 nmol/L PGF2α induced a
rapid phosphorylation of ERK1/2 (Fig. 4A, lane 2) compared with FPS cells treated for the
same period with vehicle alone (Fig. 4A, lane 1). This elevation in ERK1/2 phosphorylation
was abolished by treatment of FPS cells with PD98059 (Fig. 4A, lane 3), GM6001 (Fig. 4A,
lane 4), PP2 (Fig. 4A, lane 5), or AG1478 (Fig. 4A, lane 6). These results implicate the
involvement of c-Src, MMP, and EGFR in PGF2α-FP receptor signaling to ERK1/2. To
further explore a role for the EGFR and the small GTPase Ras in the activation of ERK1/2
by PGF2α, we cotransfected FPS cells with the cDNA for c-Myc-tagged ERK with either
DN-Ras, DN-EGFR, and DN-MEK or an empty vector (pcDNA3.0). FPS cells were then
treated with either vehicle, 100 nmol/L PGF2α, or 100 nmol/L PGF2α and AL8810 for 10
minutes. The tagged ERK was immunoprecipitated with anti-c-Myc antibodies and ERK
activity was determined by Western blotting as described in Materials and Methods. PGF2α
rapidly phosphorylated ERK1/2 in FPS cells (Fig. 4B, lane 2). This activation of ERK1/2
was abolished by cotreatment with the FP receptor antagonist (AL8810, Fig. 4B, lane 3) or
by cotransfection with the DN-Ras (Fig. 4B, lane 4), DN-EGFR (Fig. 4B, lane 5), and DN-
MEK (Fig. 4B, lane 6). Preliminary proteomic phosphosite array studies (Kinexus
Bioinformatics Corp., Vancouver, British Columbia, Canada) done by our laboratory
showed that the predominant isoforms of protein kinase C (PKC) activated by prostanoids in
our Ishikawa cells were PKCα, PKCβ1, and PKCβ2.4 We investigated whether PGF2α-FP
signaling to ERK1/2 occurred via activation of these PKC isoforms by cotransfecting FPS
cells with the cDNA for c-Myc-tagged ERK with either DN-PKCα, DN-PKCβ1, or DN-
PKCβ2 or an empty vector (pcDNA3.0). FPS cells were then treated with either vehicle or
100 nmol/L PGF2α for 10 minutes and the cells were immunoprecipitated and
immunoblotted as described above. No reduction in ERK phosphorylation was observed in
cells transfected with the DN-PKCα (Fig. 4C, lane 3), DN-PKCβ1 (Fig. 4C, lane 4), or DN-
PKCβ2 (Fig. 4C, lane 5), implicating that PGF2α-FP receptor signaling to ERK1/2 did not
occur via these PKC isoforms (Fig. 4C). We further coincubated FPS cells with the specific
PKC inhibitor GF109203X (data not shown), which also did not abolish the PGF2α-induced
activation of ERK1/2, confirming that PKC was not involved in the PGF2α-induced
activation of ERK1/2.
The involvement of the EGFR in transducing ERK1/2 signaling in FPS cells was confirmed
using RNA interference. FPS cells were transfected with either control random siRNA or
siRNA duplexes targeted against the EGFR. FPS cells were treated with either vehicle or
100 nmol/L PGF2α for 10 minutes. ERK1/2 phosphorylation was significantly reduced in
cells transfected with EGFR siRNA (Fig. 4D, lane 3) compared with FPS cells transfected
with control random siRNA (Fig. 4D, lane 2). EGFR levels in cells transfected with EGFR
siRNA (Fig. 4D, lane 3) was significantly reduced by 68.2 ± 1.3% compared with control
transfected cells (Fig. 4D, lane 2; P < 0.05).
Prostaglandin F2α-FP receptor stimulation transactivates the epidermal growth factor
receptor
Because ERK1/2 signaling in FPS cells could be inhibited by the EGFR protein tyrosine
kinase inhibitor AG1478 as well as by transfecting FPS cells with DN-EGFR or by targeted
down-regulation of EGFR with RNA interference, we investigated PGF2α-induced
transphosphorylation of the EGFR in FPS cells. Ishikawa FPS cells were treated with 100
4K.J. Sales and H.N. Jabbour, unpublished observation.
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nmol/L PGF2α or vehicle and EGFR tyrosine phosphorylation was assessed by
immunoprecipitation and Western blotting. A significant increase in EGFR tyrosine
phosphorylation compared with vehicle stimulation was observed in Ishikawa FPS cells
stimulated with PGF2α (Fig. 4E, lane 2). Treatment of cells with AL8810 (Fig. 4E, lane 3),
AG1478 (Fig. 4E, lane 4), GM6001 (Fig. 4E, lane 5), or PP2 (Fig. 4E, lane 6) significantly
reduced the PGF2α-induced EGFR tyrosine phosphorylation (P < 0.05).
Prostaglandin F2α-FP receptor activation induces vascular endothelial growth factor
expression and secretion in Ishikawa cells
The role of PGF2α-FP receptor signaling on the expression of VEGF was investigated by
quantitative RT-PCR analysis after stimulation of WT, FPS, and FPAS cells with 100 nmol/
L PGF2α or vehicle for 0, 2, 4, 8, and 24 hours. As shown in Fig. 5A, PGF2α stimulation
resulted in a significant fold increase in the expression of VEGF in Ishikawa FPS cells at 4,
8, and 24 hours (P < 0.01). However, no such increase in the expression of VEGF was
observed in WT or FPAS cells. Treatment of cells with PGF2α and AL8810 significantly
reduced the PGF2α-induced expression of VEGF mRNA at 8 hours (Fig. 5B; P < 0.05),
indicating that the effect of PGF2α on VEGF is exerted via the FP receptor. We next
investigated whether VEGF protein was secreted in the culture medium of FPS cells treated
with 100 nmol/L PGF2α. As shown in Fig. 5C, PGF2α treatment of FPS cells induced a
significant elevation in VEGF protein in the culture medium at 24 hours (P < 0.01).
Cotreatment of cells with PGF2α and AL8810 abolished the secretion of VEGF into the
culture medium (P < 0.05). No significant elevation in secreted VEGF protein was observed
in FPS cells at earlier time points and no elevation in VEGF protein secretion was observed
in WT and FPAS cells following treatment with PGF2α (data not shown).
The role of the EGFR and ERK1/2 signaling pathways in mediating the effects of PGF2α-FP
interaction on the expression of VEGF in FPS cells was investigated by quantitative RT-
PCR analysis. As shown in Fig. 5D, treatment of FPS cells with 100 nmol/L PGF2α
produced a 4.2 ± 0.4–fold increase in VEGF mRNA expression, which was significantly
reduced by the EGFR tyrosine kinase inhibitor AG1478 (P < 0.05) and abolished by the
selective MEK inhibitor PD98059 (P < 0.05). To further confirm that VEGF expression was
mediated via the EGFR and Ras-MEK-ERK1/2 pathways, we used a luciferase reporter
plasmid in which the full-length VEGF 5′ flanking sequence was fused to the firely
luciferase coding sequence in the pGL3-basic vector (25). Additionally, a luciferase reporter
without any VEGF promoter sequences (pGL3-basic) was used as a control. Cells were
cotransfected with the pRL-TK (Renilla luciferase vector as an internal control) with either
DN-Ras, DN-EGFR, and DN-MEK or an empty vector (pcDNA3.0) as a control. As shown
in Fig. 5E, treatment of control vector-transfected cells with 100 nmol/L PGF2α
significantly elevated VEGF promoter activity by 2.5 ± 0.1–fold (P < 0.01). This elevation
in VEGF promoter activity was abolished by cotreatment of the cells with PGF2α and
AL8810 and significantly reduced by cotransfection of cells with DN-EGFR, DN-Ras, or
DN-MEK (P < 0.01). Cells transfected with the control luciferase reporter, without any
VEGF sequence (pGL3-basic), showed no significant alteration in luciferase activity in
response to treatment (Fig. 5E).
Prostaglandin F2α-FP receptor activation induces the expression of vascular endothelial
growth factor in endometrial adenocarcinomas via transactivation of the epidermal growth
factor receptor
To correlate our findings obtained using the Ishikawa FP receptor model system with PGF2α
signaling to VEGF in endometrial adenocarcinomas in vivo, we also used endometrial
adenocarcinoma tissue explants. Endometrial adenocarcinoma tissues were treated with 100
nmol/L PGF2α or vehicle alone for 10 minutes and EGFR phosphorylation was assessed by
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Western blotting. A significant increase in tyrosine phosphorylation of EGFR was observed
in endometrial adenocarcinoma explants (Fig. 6A, lane 2; P < 0.05) in response to
stimulation with PGF2α compared with control tissue (Fig. 6A, lane 1; P < 0.05). Treatment
of endometrial adenocarcinoma explants with AL8810 or AG1478 abolished this action of
PGF2α (Fig. 6A, lanes 3 and 4, respectively; P < 0.05). We next incubated endometrial
adenocarcinoma explants with either vehicle or PGF2α in the absence or presence of
AL8810, AG1478, or PD98059 for 24 hours and assessed VEGF mRNA expression by
quantitative RT-PCR analysis (Fig. 6B). PGF2α significantly elevated the expression of
VEGF in endometrial adenocarcinoma explants by 4.9 ± 0.4–fold compared with vehicle-
treated tissue (P < 0.01). This elevation in expression of VEGF was significantly inhibited
by cotreatment of tissue explants with AL8810, AG1478, and PD98059 (P < 0.05). These
data obtained from the endometrial adenocarcinoma explants agree with the data obtained in
the Ishikawa cell FP receptor model system and imply that PGF2α-FP receptor interaction
can potentiate tumor angiogenesis in endometrial adenocarcinomas by enhancing the
expression of proangiogenic factors, such as VEGF, following the activation of the EGFR
and ERK1/2 pathways mediated by the actions of c-Src and MMPs (Fig. 6C).
Discussion
A relationship between PGF2α and vascular dysfunction of the endometrium has been
described (13, 27, 28). Elevated PGF2α concentrations of up to 2 μmol/L have been reported
in the menstrual fluid of women with dysmenorrhea (7). This concentration is 10-fold
greater than that observed for normal women with painless periods (7). In addition, a
correlation between PGF2α concentration and excessive menstrual blood loss has also been
reported in patients diagnosed with menorrhagia (13, 28, 29). Recent findings in our
laboratory have shown elevated COX-2 expression and synthesis and signaling of
prostanoids, including PGF2α, in human endometrial adenocarcinomas (4). Moreover, we
have recently reported elevated expression of the FP receptor in endometrial
adenocarcinomas compared with normal endometrium and ascertained a role for PGF2α-FP
receptor signaling in tumorigenesis by enhancing proliferation of endometrial
adenocarcinoma cells (6). In the present study, we show colocalized and elevated expression
of FP receptor and VEGF within the glandular epithelial cells and endothelial cells lining the
blood vessels in endometrial adenocarcinomas. These findings suggest a possible paracrine
regulation of tumor vascular function by PGF2α via the FP receptor.
To elucidate the molecular mechanisms whereby PGF2α, via the FP receptor, could
modulate the expression of proangiogenic factors, such as VEGF, and thereby promote
tumor angiogenesis, we overexpressed FP receptor in Ishikawa cells by introducing the FP
receptor cDNA in the sense and antisense orientations. This was done to raise the levels of
FP receptor in the Ishikawa cell line to the levels observed in endometrial adenocarcinomas
to create a model system that best represents FP receptor signaling in endometrial
adenocarcinoma in vivo. Furthermore, because at least nine prostanoid receptors have been
detected to date, any attempt to dissect out the signaling of a given receptor is made difficult
due to the multiplicity of different signaling pathways and complex networks of cross-talk
between them. Hence, our model presented here provides a unique opportunity to dissect out
the signaling of a single receptor (i.e., the FP receptor). Elevated FP receptor expression in
Ishikawa FPS cells compared with WT and FPAS cells was confirmed by Western blot
analysis, immunofluorescence microscopy, and accumulation of inositol phosphate and
localized to the plasma membrane, indicating that the overexpressed receptors were
trafficked to the correct intracellular compartment. The expression of FP receptor in FPS
cells also correlated closely with levels of expression of FP receptor in endometrial
adenocarcinomas, and the increase in inositol phosphate accumulation in FPS cells
compared with WT and FPAS cells was similar to that observed in endometrial
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adenocarcinoma explants stimulated with PGF2α, which we reported previously (6). We
therefore propose that the Ishikawa FP receptor cell line is a good model system for
investigating the molecular signal transduction pathways mediating the role of PGF2α in
endometrial adenocarcinoma cells via the FP receptor, which may be involved in the
development and/or progression of endometrial tumors in vivo.
The integrated response to GPCR coupling results in activation of numerous effector
signaling pathways, including the MAPK pathway (30). The MAPK pathway is a key
signaling mechanism that regulates many cellular functions, such as growth, differentiation,
and transformation (30, 31). The upstream component of the ERK-MAPK pathway is the
GTPase Ras, which activates the serine/threonine kinase Raf that in turn phosphorylates and
activates ERK1/2 (32, 33). We examined PGF2α activation of the downstream MAPK
cascades (ERK, p38, and JNK). We found that, within our experimental paradigms, PGF2α
induced a rapid increase in ERK (but not p38 or JNK) phosphorylation. This PGF2α-induced
effect was significantly elevated in FPS cells compared with WT and FPAS cells and was
mediated via the FP receptor, because ERK1/2 phosphorylation in FPS cells could be
abolished by cotreatment of the cells with the specific FP receptor antagonist (AL8810).
Furthermore, we have shown that PGF2α-induced phosphorylation of ERK1/2 in FPS cells
occurs in a c-Src-, MMP-, EGFR-, and Ras-dependent manner, because ERK1/2
phosphorylation could be inhibited with specific chemical inhibitors of c-Src (PP2), MMP
(GM6001), and EGFR kinase (AG1478) or by cotransfection of FPS cells with DN-EGFR,
DN-Ras, and DN-MEK or by siRNA targeted against the EGFR. Interestingly, we observed
that PGF2α-induced phosphorylation of ERK1/2 occurred independently of PKC activation.
Recent data in our laboratory have indicated that transphosphorylation of the EGFR by
PGF2α is crucial for transducing mitogenic signaling and cell growth (6). Several
mechanisms are proposed for the transactivation of EGFR by GPCRs (34-36). One of these
mechanisms involves the activation of transmembrane MMP and extracellular release of
heparin-binding EGF (HB-EGF) from its latent membrane-spanning precursor in the plasma
membrane. Once cleaved, the HB-EGF ligand can associate with and activate the EGFR and
induce ERK1/2 activation. Alternatively, activation the EGFR can also occur via the
activation of the c-Src family of nonreceptor tyrosine kinases (34-36). We found that the
effect of PGF2α on the transphosphorylation of EGFR and ERK activation in FP receptor–
expressing Ishikawa cells seems to be mediated by c-Src as well as MMPs. Recently,
Guerrero et al. (37) have also shown transactivation of the EGFR by c-Src as well as MMPs,
suggesting that EGFR signaling can be mediated via an intracellular c-Src-dependent as well
as extracellular MMP-dependent mechanism coactivated in the same cell in a cell context–
dependent manner.
Tumor growth is dependent on angiogenesis. To sustain and facilitate growth in an
environment where oxygen and nutrients are limiting, cancer cells produce a variety of
factors, including VEGF, to create a proangiogenic environment and promote
neovascularization (38, 39). VEGF is a heparin-binding glycoprotein having potent
angiogenic, mitogenic, and vascular permeability-enhancing properties that are specific for
endothelial cells (40). Our data show that PGF2α-FP receptor activation results in elevated
expression and secretion of VEGF in Ishikawa FP cells and endometrial adenocarcinoma
explants. Our approach using chemical inhibitors of signal transduction or DN mutant
isoforms of signaling effectors confirm further the involvement of the EGFR to ERK1/2
signaling in the activation of VEGF expression and secretion following PGF2α-FP receptor
interaction. Elevated VEGF expression and secretion would in turn exert a paracrine
function on endothelial cells to promote angiogenesis, thus enhancing blood flow to the
tumor and creating an environment to sustain tumor growth. Such a mechanism has been
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proposed for the action of another prostanoid (i.e., prostaglandin E2), via its interaction with
the EP2 receptor (20, 38, 41, 42).
Taken together, our findings using the Ishikawa FP receptor model system and which have
been confirmed using endometrial adenocarcinoma explants show for the first time that
PGF2α-FP receptor interaction can promote the transcription and release of a potent
proangiogenic factor (i.e., VEGF) via the transactivation of the EGFR leading to ERK1/2
signaling as depicted schematically in Fig. 6C. Moreover, we propose that targeted
inhibition of FP receptor, EGFR, and ERK function in endometrial carcinomas could
effectively block the signaling and transcription of target genes, such as VEGF, associated
with angiogenesis. High EGFR levels in endometrial cancer have been correlated with poor
histopathologic grading, greater invasiveness, and reduced patient survival (43, 44).
Blockade of EGFR signaling with an orally active EGFR tyrosine kinase inhibitor has been
used successfully in carcinomas of nude mice to inhibit tumor angiogenesis by reducing
VEGF expression (45). Similarly, the use of an orally active inhibitor of the Ras-ERK
cascade has been proven efficacious in treatment of metastatic melanoma (46). Recently,
Torrance et al. (47) have shown that a combinatorial approach using a nonselective COX
enzyme inhibitor in combination with an inhibitor of EGFR kinase can reduce polyp
formation in APCΔ716 mice more effectively than either compound on their own (47). In
light of this latter finding and our observations presented herein, an ERK inhibitor or EGFR
tyrosine kinase inhibitor in combination with a FP receptor antagonist may be of clinical
relevance as an efficacious therapy for women with endometrial adenocarcinoma. Our data
may also have relevance for other endometrial pathologies that are associated with disturbed
vascular function and elevated prostanoid biosynthesis, such as menorrhagia, dysmenorrhea,
and endometriosis.
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Figure 1.
A, relative mRNA expression of FP receptor and VEGF in endometrial adenocarcinoma (n =
25) and normal endometrium (n = 10) as determined by real-time quantitative RT-PCR
analysis. B, localization of the site of expression of FP receptor (red) and VEGF (green) and
colocalization of FP receptor with VEGF (merged; yellow) in poorly (P), moderately (M),
and well-differentiated (W) endometrial adenocarcinomas, respectively. Arrow, blood vessel
under high magnification. Bar, 100 μm. C, localization of the site of expression of FP
receptor (red) and CD31 (green) and colocalization of FP receptor with CD31 (merged;
yellow) in the endothelial cells of the blood vessels. Representative sample of a moderately
differentiated adenocarcinoma. Insets, negative controls. Bar, 10 μm. P < 0.05, b is
significantly different from a.
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Figure 2.
A, representative Western blot of FP receptor expression in WT, FPS, and FPAS cells. Cells
were immunoblotted with specific FP receptor antibody and normalized for loading against
β-actin on the same blot. B, immunofluorescence microscopy done on WT, FPS, and FPAS
cells using a specific FP receptor primary antibody. Control cells (C) were incubated with
normal IgG in place of primary antibody (representative FPS cells incubated with IgG). C,
relative expression of FP receptor mRNA in endometrial adenocarcinoma (n = 25) and
normal endometrial tissues (n = 10) compared with FP receptor mRNA expression in
Ishikawa WT and FPS cell lines. D, inositol phosphate (IP) accumulation was assessed in
WT, FPS, and FPAS cells in response to administration of vehicle, 100 nmol/L PGF2α, or
100 nmol/L PGF2α and increasing doses of specific FP receptor antagonist AL8810.
Columns, mean of three independent experiments; bars, SE. P < 0.05, b is significantly
different from a.
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Figure 3.
Effect of PGF2α on ERK1/2 signaling in WT, FPS, and FPAS Ishikawa cells. A, Ishikawa
cells were stimulated with 100 nmol/L PGF2α for 0, 10, and 30 minutes and subjected to
immunoblot analysis using antibody against phosphorylated ERK1/2 (top). The total amount
of ERK in cell lysates was determined by reprobing the same blot with antibody recognizing
total protein (bottom). B, Ishikawa WT, FPS, and FPAS cells were pretreated for 1 hour
with increasing doses of specific FP receptor antagonist (AL8810) or vehicle followed by
stimulation with vehicle, 100 nmol/L PGF2α, or PGF2α and antagonist for 10 minutes. For
each, a representative Western blot is shown, with semiquantitative analysis of ERK
phosphorylation determined as described in Materials and Methods. Columns, mean of four
independent experiments; bars, SE. P < 0.05, b is significantly different from a; P < 0.01, c
is significantly different from a and b. -, absence of agent; +, presence of agent.
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Figure 4.
Representative Western blots showing activation of ERK1/2 and EGFR signaling in FPS
Ishikawa cells. A, FPS cells were pretreated for 1 hour with inhibitors or vehicle followed
by stimulation with vehicle (control; lane 1), 100 nmol/L PGF2α (lane 2), 100 nmol/L
PGF2α and PD98059 (lane 3), 100 nmol/L PGF2α and GM6001 (lane 4), 100 nmol/L PGF2α
and PP2 (lane 5), and 100 nmol/L PGF2α and AG1478 (lane 6) for 10 minutes. B, Ishikawa
FPS cells were transfected with c-Myc-tagged ERK cDNA together with pcDNA3 (control
empty vector) cDNA or cDNA encoding DN-Ras, DN-EGFR, or DN-MEK. Cells were
pretreated for 1 hour with 50 μmol/L AL8810 or vehicle followed by stimulation with
vehicle (control), 100 nmol/L PGF2α, or 100 nmol/L PGF2α and 50 μmol/L AL8810 for 10
minutes. C, Ishikawa FPS cells were transfected with c-Myc-tagged ERK cDNA together
with pcDNA3 cDNA or cDNA encoding DN-PKCα, DN-PKCβ1, and DN-PKCβ2. Cells
were stimulated with vehicle (control) or 100 nmol/L PGF2α for 10 minutes. D, Ishikawa
FPS cells were transfected with control random siRNA or siRNA targeted against the
EGFR. Cells were stimulated with vehicle or 100 nmol/L PGF2α for 10 minutes and
subjected to immunoblot analysis for phosphorylated ERK1/2, total ERK, or
immunoprecipitated (IP) and immunoblotted (WB) with antisera against EGFR (bottom). E,
representative Western blot showing PGF2α transactivation of EGFR signaling in FPS cells.
FPS cells were pretreated for 1 hour with inhibitors, antagonist, or vehicle followed by
stimulation with vehicle (control; lane 1), 100 nmol/L PGF2α (lane 2), 100 nmol/L PGF2α
and AL8810 (lane 3), 100 nmol/L PGF2α and AG1478 (lane 4), 100 nmol/L PGF2α and
GM6001 (lane 5), and 100 nmol/L PGF2α and PP2 (lane 6) for 10 minutes. After lysis,
EGFR was immunoprecipitated with anti-EGFR antibody and tyrosine-phosphorylated
EGFR was detected by immunoblotting with anti-phospho-EGFR antibody (top). The total
amount of EGFR in immunoprecipitates was determined by reprobing the same blot with
anti-EGFR antibody (bottom). Immunoblots were quantified as described in Materials and
Methods. Columns, mean of four independent experiments; bars, SE. P < 0.05, b is
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significantly different from a; P < 0.01, c is significantly different from a and b. -, ab- sence
of agent; +, presence of agent.
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Figure 5.
VEGF expression and secretion in Ishikawa cells. A, VEGF expression in Ishikawa WT,
FPS, and FPAS cells was measured by real-time quantitative RT-PCR analysis following
treatment of cells for 0, 2, 4, 8, and 24 hours with vehicle or 100 nmol/L PGF2α. B, VEGF
expression in FPS cells at 8 hours. Cells were treated with 100 nmol/L PGF2α in the absence
or presence of FP receptor antagonist (AL8810). C, secretion of VEGF protein into the
culture medium of FPS cells was measured by ELISA. FPS cells were treated for 24 hours
with vehicle, 100 nmol/L PGF2α, or 100 nmol/L PGF2α and AL8810. D, VEGF expression
in Ishikawa FPS cells in response to treatment with chemical inhibitors of EGFR and ERK
signaling as measured by real-time quantitative RT-PCR analysis. Cells were treated for 8
hours with vehicle or 100 nmol/L PGF2α. In parallel, cells were treated with 100 nmol/L
PGF2α and AG1478 or 100 nmol/L PGF2α and PD98059. E, VEGF promoter activity in
FPS cells transfected with the full-length VEGF firefly luciferase promoter (pGL3-VEGF-
luc; filled columns) or empty firefly luciferase control vector (pGL3-basic; open columns).
FPS cells were transfected with pGL3-basic or pGL3-VEGF-luc and pRL-TK (Renilla
luciferase) and cotransfected with either pcDNA3 (control empty vector cDNA) or cDNA
encoding DN-Ras, DN-EGFR, and DN-MEK. Following transfection, the cells were
incubated for 8 hours with either vehicle, 100 nmol/L PGF2α, or 100 nmol/L PGF2α and
AL8810, and firefly and Renilla luciferase activity was measured for the calculation of
specific VEGF promoter activity as described in Materials and Methods. Columns, mean of
four independent experiments; bars, SE. P < 0.05, b is significantly different from a; P <
0.01, c is significantly different from a and b. -, absence of agent; +, presence of agent.
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Figure 6.
PGF2α transactivation of the EGFR and activation of VEGF in endometrial
adenocarcinomas. A, endometrial adenocarcinoma biopsy explants were pretreated for 1
hour with inhibitors or vehicle followed by stimulation with vehicle (control, lane 1), 100
nmol/L PGF2α (lane 2), 100 nmol/L PGF2α and AL8810 (lane 3), or 100 nmol/L PGF2α and
AG1478 (lane 4) for 10 minutes. After lysis, EGFR was immunoprecipitated with anti-
EGFR antisera and tyrosine-phosphorylated EGFR was detected by immunoblotting with
anti-phospho-EGFR antibody. The total amount of EGFR in immunoprecipitates was
determined by reprobing the same blot with total EGFR antibody. Semiquantitative analysis
of EGFR phosphorylation was determined as described in Materials and Methods. B, VEGF
mRNA expression in endometrial adenocarcinoma in response to 100 nmol/L PGF2α as
determined by quantitative RT-PCR analysis. Endometrial adenocarcinoma explants were
treated with vehicle, 100 nmol/L PGF2α, 100 nmol/L PGF2α and AL8810, 100 nmol/L
PGF2α and AG1478, and 100 nmol/L PGF2α and PD98059 for 24 hours. Columns, mean of
four independent experiments; bars, SE. P < 0.05, b is significantly different from a; P <
0.01, c is significantly different from a and b. -, absence of agent; +, presence of agent. C,
schematic representation of PGF2α-FP receptor signaling to ERK in endometrial
adenocarcinoma cells. Intracellular PGF2α produced via the actions of COX enzymes is
actively transported out of the cell (PGT) and interacts with FP receptors in an autocrine/
paracrine manner to activate inositol-1,4,5-trisphosphate. Activation of inositol phosphate
can potentially initiate ERK signaling via the activation of c-Src and MMPs and
transphosphorylation of the EGFR, culminating in the transcription and release of VEGF to
promote tumor angiogenesis by acting on adjacent endothelial cells.
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